| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Akebia Therapeutics (NASDAQ:AKBA) is gearing up to announce its quarterly earnings on Thursday, 2025-05-08. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Akebia Therapeutics will report an earnings per share (EPS) of $-0.04.
The announcement from Akebia Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
During the last quarter, the company reported an EPS missed by $0.02, leading to a 33.73% increase in the share price on the subsequent day.
Here's a look at Akebia Therapeutics's past performance and the resulting price change:
| Quarter | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.08 | -0.06 | -0.05 | -0.08 |
| EPS Actual | -0.10 | -0.10 | -0.04 | -0.09 |
| Price Change % | 34.0% | 4.0% | -7.000000000000001% | -9.0% |
Shares of Akebia Therapeutics were trading at $2.32 as of May 06. Over the last 52-week period, shares are up 80.08%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for Akebia Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AKBA
